Treatment of rheumatic immune-related adverse events due to cancer immunotherapy with immune checkpoint inhibitors—is it time for a paradigm shift?
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1434-9949
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Treatment of rheumatic immune-related adverse events due to cancer immunotherapy with immune checkpoint inhibitors—is it time for a paradigm shift? ; day:28 ; month:9 ; year:2020 ; pages:1-9
Clinical rheumatology ; (28.9.2020), 1-9
- Creator
-
Chatzidionysiou, Katerina
Liapi, Matina
Tsakonas, Georgios
Gunnarsson, Iva
Catrina, Anca
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s10067-020-05420-w
- URN
-
urn:nbn:de:101:1-2020111721395460509700
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:35 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Chatzidionysiou, Katerina
- Liapi, Matina
- Tsakonas, Georgios
- Gunnarsson, Iva
- Catrina, Anca
- SpringerLink (Online service)
Other Objects (12)
Screening for rheumatic heart disease: is a paradigm shift required?
Immune checkpoint receptors in regulating immune reactivity in rheumatic disease
Managing immune-related adverse events in oncology
Immune-related adverse event in the emergency department: methodology of the immune-related emergency disposition index (IrEDi)
Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors
Immune-related prognosis biomarkers associated with osteosarcoma microenvironment
The immune-related role of BRAF in melanoma
Immune-related biomarkers in triple-negative breast cancer
Immune landscape and prognostic immune-related genes in KRAS-mutant colorectal cancer patients
Mechanisms of Immune-Related Complications in Cancer Patients Treated with Immune Checkpoint Inhibitors
Association of immune-related adverse events with immune checkpoint inhibitor efficacy: real or imaginary?
Sarcopenia, immune-mediated rheumatic diseases, and nutritional interventions
Screening for rheumatic heart disease: is a paradigm shift required?
Immune checkpoint receptors in regulating immune reactivity in rheumatic disease
Managing immune-related adverse events in oncology
Immune-related adverse event in the emergency department: methodology of the immune-related emergency disposition index (IrEDi)
Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors
Immune-related prognosis biomarkers associated with osteosarcoma microenvironment
The immune-related role of BRAF in melanoma
Immune-related biomarkers in triple-negative breast cancer
Immune landscape and prognostic immune-related genes in KRAS-mutant colorectal cancer patients
Mechanisms of Immune-Related Complications in Cancer Patients Treated with Immune Checkpoint Inhibitors
Association of immune-related adverse events with immune checkpoint inhibitor efficacy: real or imaginary?
Sarcopenia, immune-mediated rheumatic diseases, and nutritional interventions
Screening for rheumatic heart disease: is a paradigm shift required?
Immune checkpoint receptors in regulating immune reactivity in rheumatic disease
Managing immune-related adverse events in oncology
Immune-related adverse event in the emergency department: methodology of the immune-related emergency disposition index (IrEDi)
Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors
Immune-related prognosis biomarkers associated with osteosarcoma microenvironment
The immune-related role of BRAF in melanoma
Immune-related biomarkers in triple-negative breast cancer
Immune landscape and prognostic immune-related genes in KRAS-mutant colorectal cancer patients
Mechanisms of Immune-Related Complications in Cancer Patients Treated with Immune Checkpoint Inhibitors
Association of immune-related adverse events with immune checkpoint inhibitor efficacy: real or imaginary?